Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510228 | 1.00 | CYP11B1 (0.49) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 | |
| SCHEMBL22229677 | 0.97 | CYP11B1 (0.47) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 | |
| SCHEMBL30364453 | 0.97 | CYP11B1 (0.47) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 | |
| Phosphoric Acid SCHEMBL18641129 | 0.93 | CYP11B1 (0.47) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 | |
| SCHEMBL18912212 | 0.92 | CYP11B1 (0.44) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 | |
| SCHEMBL29805436 | 0.90 | CYP11B1 (0.45) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 | |
| SCHEMBL3923123 | 0.90 | CYP11B1 (0.45) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 | |
| SCHEMBL18912084 | 0.85 | CYP11B1 (0.40) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 | |
| SCHEMBL22229788 | 0.84 | GPR84 (0.48) | CYP11B1CYP11B2NQO1ALOX5GPR84 | |
| SCHEMBL18665816 | 0.84 | CYP11B1 (0.41) | CYP11B1CYP11B2P2RX1P2RX3P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534484-B2 | Process for preparing dimeric phosphazene derived BrØnsted acids | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2026-01-27 | — | — | US | disclosed |
| WO-2023249106-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249105-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249107-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| US-20230406870-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-12-21 | — | — | US | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116348435-A | Process for preparing dimeric phosphazene-derived bronsted acids | 科勒研究非盈利有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-3599234-B1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INT (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-10626099-B2 | Process for preparing pleuromutilin | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3599234-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3599234-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-10392353-B2 | Processes for making substituted quinazoline compounds using hydrogen bonding catalysts | MERCK SHARP & DOHME CORP. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190106400-A1 | Process For Preparing Pleuromutilin | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-04-11 | — | — | US | disclosed |
| US-10189776-B2 | Stereoselective process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-10189776-B2 | Stereoselective process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20180258031-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-09-13 | — | — | US | disclosed |
| WO-2017091453-A1 | NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS | MERCK SHARP & DOHME CORP. (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017046355-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106400-A1 | Process For Preparing Pleuromutilin | PLEC, MLN, MRPL21 | CYP11B1 2664/4885CYP11B2 2373/4885P2RX1 876/4885 |
| US-10626099-B2 | Process for preparing pleuromutilin | PLEC, MLN, MRPL21 | CYP11B1 2664/4885CYP11B2 2373/4885P2RX1 876/4885 |
| US-20230406870-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | PHOSPHO1, BRPF1, BRD9 | CYP11B1 3165/4885CYP11B2 3450/4885P2RX1 644/4885 |
| US-10189776-B2 | Stereoselective process | CYP4A11, CYP4B1, CYP3A4 | CYP11B1 9/4885CYP11B2 10/4885P2RX1 1729/4885 |
| US-12534484-B2 | Process for preparing dimeric phosphazene derived BrØnsted acids | HAT1, LBR, CD79B | CYP11B1 487/4885CYP11B2 608/4885P2RX1 3712/4885 |
| US-20180258031-A1 | STEREOSELECTIVE PROCESS | CYP4A11, CYP4B1, CYP3A4 | CYP11B1 9/4885CYP11B2 10/4885P2RX1 1729/4885 |
| US-10392353-B2 | Processes for making substituted quinazoline compounds using hydrogen bonding catalysts | NQO1, NDUFS7, NDUFS2 | CYP11B1 342/4885CYP11B2 207/4885P2RX1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.